Current Surgical Management of Ovarian Cancer
Section snippets
Surgical staging
Typically, an adnexal mass is suspected by symptom history or findings on pelvic examination. Alternatively, it may be discovered by serendipity on sonography or computed tomography (CT) scanning. Proper identification of an ovarian malignancy among patients with a pelvic mass may be aided by imaging characteristics of the mass and the rest of the abdomen, in addition to the preoperative CA125 level. More recently, the human epididymis 4 (HE4) serum marker has been approved for use in helping
Tumor debulking
Ovarian cancer is often portrayed as the disease that whispers because it does not present with dramatic bleeding, excruciating pain, or an obvious lump. Instead, the typical symptoms tend to be indolent. Patients and their health care providers often attribute such nonspecific changes to menopause, aging, dietary indiscretions, stress, depression, or functional bowel problems. Frequently, women are medically managed for indigestion or other presumed ailments without having a pelvic
Palliative surgery
Patients with relapsed ovarian cancer frequently develop bowel obstructions at some point in their treatment course. Bowel obstruction is the most common reason for hospital admission during the last year of life in patients with ovarian carcinoma.73 Often, patients can initially be managed by nasogastric suction and bowel rest. However, at some point, patients with continued progressive disease will develop worsening symptoms. If not previously addressed, such events should be incorporated
References (78)
- et al.
Patterns of care in surgery for ovarian cancer in Europe
Eur J Surg Oncol
(2010) - et al.
A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?
Gynecol Oncol
(2002) - et al.
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
Gynecol Oncol
(2009) - et al.
SGO White Paper on ovarian cancer: etiology, screening and surveillance
Gynecol Oncol
(2010) - et al.
Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications
J Am Coll Surg
(2003) - et al.
Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging
Gynecol Oncol
(2011) - et al.
Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas
Gynecol Oncol
(2001) - et al.
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study
Gynecol Oncol
(2010) - et al.
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers
Am J Obstet Gynecol
(2005) - et al.
Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer?
J Minim Invasive Gynecol
(2009)
Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy
Gynecol Oncol
The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease
Gynecol Oncol
Retrospective cohort study of surgical staging for ovarian low malignant potential tumors
Am J Obstet Gynecol
Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis
Obstet Gynecol
Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?
Gynecol Oncol
Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy
Gynecol Oncol
Fertility-sparing surgery for ovarian low malignant potential tumors
Gynecol Oncol
Surgical management of malignant ovarian germ-cell tumors: 10 years’ experience of 129 patients
Obstet Gynecol
A critique of surgical cytoreduction in advanced ovarian cancer
Gynecol Oncol
Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer
Gynecol Oncol
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer
Gynecol Oncol
Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience
J Am Coll Surg
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
Gynecol Oncol
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
Gynecol Oncol
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
Gynecol Oncol
Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer
Gynecol Oncol
Laparoscopic-assisted cytoreduction for primary advanced ovarian cancer: success, morbidity and survival
Gynecol Oncol
Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease
Gynecol Oncol
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis
Gynecol Oncol
Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction
Gynecol Oncol
The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists
Gynecol Oncol
Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?
Gynecol Oncol
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis
Gynecol Oncol
Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome
Gynecol Oncol
Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer
Gynecol Oncol
Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer
Int J Gynaecol Obstet
Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series
Gynecol Oncol
Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Gynecol Oncol
Clinical disease course during the last year in ovarian cancer
Gynecol Oncol
Cited by (46)
Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer
2024, Critical Reviews in Oncology/HematologyTorsion of juvenile granulosa cell ovarian tumor
2022, Journal of Pediatric Surgery Case ReportsCitation Excerpt :Fertility-sparing surgery is preferred in children, adolescents, and women when fertility preservation is desired. There is no need for hysterectomy in stage I tumors as long as the contralateral tube and ovary and the uterus are unaffected, unilateral salpingo-oophorectomy with examination of the contralateral ovary is likely sufficient [14–16]. The negative preoperative tumor markers in our patient did not rule out malignancy.
M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients
2021, Gynecologic OncologyCitation Excerpt :The selection of this very high-risk population was based on achieving a relevant number of recurrences during the 18-month study follow-up period to evaluate the safety and efficacy objectives of the trial. For the stage III-IV patient population, literature shows that the median OS ranges from 24 to 50 months [3,17–21], while PFS is only 12–21 months [16–18,22]. Of the 23 subjects included, 15 patients underwent device removal due to disease progression within the 18-month study duration (65.2%), with a median PFS rate similar to that published despite including patients with a very high risk of recurrence.
Surgery in early-stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled “Initial management of patients with epithelial ovarian cancer” developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa
2019, Gynecologie Obstetrique Fertilite et SenologiePlatinum Chemotherapy Hypersensitivity: Prevalence and Management
2017, Immunology and Allergy Clinics of North AmericaCitation Excerpt :As an example, it is well-described that ovarian cancer is the most fatal gynecologic malignancy.2 The standard treatment approach for newly diagnosed ovarian cancer involves multidisciplinary treatment, including surgical cytoreduction followed by a platinum-based therapy.3,4 Despite achieving initial complete clinical remission, the vast majority will go on to develop recurrent ovarian cancer.5
No funding disclosures.